高级检索
当前位置: 首页 > 详情页

A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Dept Surg, Wuhan Hosp 4, Puai Hosp,Tongji Med Coll, 67 Jiefang Ave, Wuhan 430033, Hubei, Peoples R China [2]Huazhong Univ Sci & Technol,Key Lab Organ Transplantat,Minist Hlth,Inst Organ Transplantat,Tongji Hosp,Tongji Med Co,Wuhan,Hubei,Peoples R China [3]Minist Educ, Key Lab Organ Transplantat, Wuhan, Hubei, Peoples R China [4]Wuhan Univ, Dept Breast Surg, Renmin Hosp, Wuhan, Hubei, Peoples R China [5]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Gastroenterol,Wuhan,Hubei,Peoples R China
出处:
ISSN:

关键词: MyD88 Epithelial-mesenchymal transition Renal interstitial fibrosis NF-kappa B Transforming growth factor beta 1

摘要:
Background/Aims: The TLR/MyD88/NE-KB signaling pathway has been successfully used to treat renal interstitial fibrosis (RIF). However, the exact therapeutic mechanism is still unknown. Here, we assessed the therapeutic efficacy of TJ-M2010-2, a small molecular compound that inhibits MyD88 homodimerization, in RIF induced by ischemia reperfusion injury (IRO. Methods: In vivo, RIF was induced in mice by IRI, and the mice were prophylactically treated with TJ-M2010-2. In vitro, HK-2 cells were incubated with TGF-p1 to induce EMT, and the cells were pretreated with TJ-M2010-2. Results: We found that, compared with the IRI group, the TJ-M2010-2 group showed marked attenuation of RIF and renal function injury; decreased expression of TGE-beta 1, a-SMA, vimentin. MMP2 and MMP9; and increased E-cadherin expression. Furthermore, TGF-beta 1-induced EMT was blocked by TJ-M2010'2 in HK-2 cells, as evidenced by blocked morphologic transformation, restored E-cadherin expression and inhibited a-SMA expression. In addition, compared to the TGF-p1 group, the TJ-M2010-2 group showed profound inhibition of the expression of TRAF6, p65 and Snail and upregulation of the expression of IKBa. Conclusion: This MyD88 inhibitor may be a potential therapeutic agent to ameliorate RIF. (C) 2018 The Auther(s) Published by S. Karger AG, Basel

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 外周血管病 3 区 生理学 3 区 泌尿学与肾脏学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 生理学 4 区 外周血管病 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2016]版:
Q2 UROLOGY & NEPHROLOGY Q2 PHYSIOLOGY Q2 PERIPHERAL VASCULAR DISEASE
最新[2023]版:
Q2 PERIPHERAL VASCULAR DISEASE Q2 UROLOGY & NEPHROLOGY Q3 PHYSIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Dept Surg, Wuhan Hosp 4, Puai Hosp,Tongji Med Coll, 67 Jiefang Ave, Wuhan 430033, Hubei, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:0 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)